ADT Inc. has officially entered into a definitive agreement to be acquired by Thrive Holdings in a transaction valued at $15.3 billion. This significant move is expected to bolster ADT's capabilities in the security services sector, leveraging Thrive's technological expertise.
The acquisition is anticipated to close in the first quarter of 2027, subject to customary closing conditions, including stockholder approval and regulatory clearance. Once completed, ADT will operate as a private company, marking a new chapter for the firm.
Background
ADT Inc., classified under the SIC code 7381, specializes in services related to detective, guard, and armored car services. The company is listed on the New York Stock Exchange under the ticker symbol ADT. ADT has a long history of providing security solutions, with over 150 years of experience in the industry.
What the Filing Says
The recent SEC filing indicates that ADT has communicated its acquisition plans to partners via email, emphasizing that the transaction will not alter existing partnership agreements. The email stated, "We are excited about this next chapter with Thrive Holdings," highlighting the expected benefits of combining ADT's security expertise with Thrive's technology capabilities.
Impact
This acquisition may significantly affect ADT's current partnerships and operational strategies. The company reassured partners that their existing agreements would remain intact and that they would continue to focus on delivering value to customers. The collaboration with Thrive Holdings is expected to enhance ADT's ability to invest in innovative products and services.
What's Next
The transaction is set to close in the first quarter of 2027, pending stockholder approval and necessary regulatory approvals. The filing does not specify any further immediate actions required from ADT or its stakeholders.
Read Next
Westlake BioPartners Discloses Major Stake in Latigo Biotherapeutics
Westlake BioPartners Acquires Significant Stake in Electra Therapeutics
Coletti Reports New Stock Transactions for Cintas Corp
Bain Capital Life Sciences acquires 9.99% stake in ADC Therapeutics
Studio City International Holdings reports major share transactions
Saba Capital Management acquires shares in New Germany Fund






